Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

[Psychosis, cardiovascular risk and associated mortality: are we on the right track?].

Castillo Sánchez M, Fàbregas Escurriola M, Bergè Baquero D, Goday Arno A, Vallès Callol JA.

Clin Investig Arterioscler. 2014 Jan-Feb;26(1):23-32. doi: 10.1016/j.arteri.2013.05.006. Epub 2013 Jul 23. Review. Spanish.

PMID:
23890424
2.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly..

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
3.

Development of a health screening clinic.

Millar HL.

Eur Psychiatry. 2010 Jun;25 Suppl 2:S29-33. doi: 10.1016/S0924-9338(10)71703-X.

PMID:
20620883
4.

Life expectancy and cardiovascular mortality in persons with schizophrenia.

Laursen TM, Munk-Olsen T, Vestergaard M.

Curr Opin Psychiatry. 2012 Mar;25(2):83-8. doi: 10.1097/YCO.0b013e32835035ca. Review.

PMID:
22249081
5.

Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis.

Foley DL, Morley KI.

Arch Gen Psychiatry. 2011 Jun;68(6):609-16. doi: 10.1001/archgenpsychiatry.2011.2. Epub 2011 Feb 7. Review.

PMID:
21300937
6.

[Higher mortality and somatic illness in a psychotic diseases].

Lindh Å, Gothefors D, Runeson B.

Lakartidningen. 2015 Oct 13;112. pii: DHD4. Review. Swedish.

PMID:
26461503
7.

Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review.

Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B, Jullien D, Aractingi S, Aubin F, Joly P, Le Maître M, Ortonne JP, Paul C, Richard MA.

J Eur Acad Dermatol Venereol. 2013 Aug;27 Suppl 3:12-29. doi: 10.1111/jdv.12163. Review.

PMID:
23845149
8.

Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: results from the CLAMORS study.

Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J; CLAMORS Study Collaborative Group..

Eur Psychiatry. 2012 May;27(4):267-74. doi: 10.1016/j.eurpsy.2010.09.001. Epub 2010 Oct 30.

PMID:
21036549
9.

Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.

Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn DL, Azrin S, Goldstein A, Severe J, Heinssen R, Kane JM.

JAMA Psychiatry. 2014 Dec 1;71(12):1350-63. doi: 10.1001/jamapsychiatry.2014.1314.

PMID:
25321337
10.

Schizophrenia and sudden cardiac death: a review.

Koponen H, Alaräisänen A, Saari K, Pelkonen O, Huikuri H, Raatikainen MJ, Savolainen M, Isohanni M.

Nord J Psychiatry. 2008;62(5):342-5. doi: 10.1080/08039480801959323. Review.

PMID:
18752109
12.

[Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].

Ames D, Camm J, Cook P, Falkai P, Gury C, Hurley R, Johnson G, Piepho R, Vieweg V; Cardiac Safety in Schizophrenia Group..

Encephale. 2002 Nov-Dec;28(6 Pt 1):552-62. French.

PMID:
12506268
13.

[Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation].

Vanuzzo D, Pilotto L, Mirolo R, Pirelli S.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):6S-17S. Review. Italian.

PMID:
18773746
14.
15.
16.

Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study.

Sawada H, Oeda T, Yamamoto K, Umemura A, Tomita S, Hayashi R, Kohsaka M, Kawamura T.

BMC Neurol. 2013 Oct 12;13:145. doi: 10.1186/1471-2377-13-145.

17.

Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.

Meltzer HY, Davidson M, Glassman AH, Vieweg WV.

J Clin Psychiatry. 2002;63 Suppl 9:25-9. Review.

18.

Metabolic risk factors in drug-naive patients with first-episode psychosis.

Verma SK, Subramaniam M, Liew A, Poon LY.

J Clin Psychiatry. 2009 Jul;70(7):997-1000. doi: 10.4088/JCP.08m04508. Epub 2009 Jun 2.

PMID:
19497246
19.

Physical consequences of schizophrenia and its treatment: the metabolic syndrome.

Ryan MC, Thakore JH.

Life Sci. 2002 Jun 7;71(3):239-57. Review.

PMID:
12034344
20.

Excess early mortality in schizophrenia.

Laursen TM, Nordentoft M, Mortensen PB.

Annu Rev Clin Psychol. 2014;10:425-48. doi: 10.1146/annurev-clinpsy-032813-153657. Epub 2013 Dec 2. Review.

PMID:
24313570

Supplemental Content

Support Center